BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24444516)

  • 1. [Introduction].
    García SD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Mauricio D
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 4. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
    Pérez López G; González Albarrán O; Cano Megías M
    Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
    Goldberg N; Fralick M
    CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
    [No Abstract]   [Full Text] [Related]  

  • 7. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 8. [Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
    Rosak C; Forst T
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():95-101. PubMed ID: 23326927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
    Zhang WB; Gong N; Wang YX
    Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):453-6. PubMed ID: 21416966
    [No Abstract]   [Full Text] [Related]  

  • 13. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
    Dalama B; Biagetti B; Mesa J
    Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
    [No Abstract]   [Full Text] [Related]  

  • 14. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
    Vallon V
    Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
    Dutta D; Kalra S
    J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
    Miller K; Miller EM
    J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world points to SGLT-2 blockers advantage.
    Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398306
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.